About the Hepatocellular Carcinoma Session
Hepatocellular carcinoma (HCC) is a primary liver cancer with rising incidence globally, spurred by chronic liver diseases like hepatitis B and C, and non-alcoholic fatty liver disease. Current cancer research is focusing on the molecular mechanisms and genetic mutations driving HCC progression. Breakthroughs in understanding the tumor microenvironment, immune evasion strategies, and angiogenesis have opened new avenues for targeted therapies. Immunotherapies, particularly checkpoint inhibitors, are showing promise in clinical trials, offering hope for improved survival rates. Additionally, advancements in liquid biopsy techniques for early detection and monitoring are enhancing personalized treatment approaches. Continuous research is vital for developing innovative strategies to combat HCC and improve patient outcomes.
Topics Covered in Hepatocellular Carcinoma
Viral Hepatitis
Fatty Liver Disease
Cirrhosis Surveillance
Locoregional Therapy
Liver Transplantation
Immunotherapy Combinations
Related Scientific Sessions at CIOC 2027
Why Attend the Hepatocellular Carcinoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Hepatocellular Carcinoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Hepatocellular Carcinoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Hepatocellular Carcinoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Hepatocellular Carcinoma Conference 2027 — FAQs
What is the Hepatocellular Carcinoma track at CIOC 2027?
The Hepatocellular Carcinoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Hepatocellular Carcinoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Hepatocellular Carcinoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Hepatocellular Carcinoma are all welcome — whether presenting or attending.
Can I present my research in the Hepatocellular Carcinoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Hepatocellular Carcinoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Hepatocellular Carcinoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.